CMBA
RIGL icon

C.M. Bidwell & Associates’s Rigel Pharmaceuticals RIGL Stock Holding History

C.M. Bidwell & Associates’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-115
Closed -$4.92K – 516
2025
Q4 		$4.92K Hold
115
– – ﹤0.01% 328
2025
Q3 		$3.26K Buy
+115
New +$3.44K ﹤0.01% 375

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

C.M. Bidwell & Associates's RIGL Position: Q1 2026 in Review

C.M. Bidwell & Associates sold out of Rigel Pharmaceuticals (RIGL) in Q1 2026, closing a stake of 115 shares — an estimated $4.92K sold.

C.M. Bidwell & Associates first reported a position in RIGL in Q3 2025 and held it in 2 quarters. The position peaked at $4.92K in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • C.M. Bidwell & Associates reported no remaining Rigel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 115 Rigel Pharmaceuticals shares in Q1 2026, an estimated $4.92K.
  • C.M. Bidwell & Associates first reported a position in Rigel Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • C.M. Bidwell & Associates's Rigel Pharmaceuticals position peaked at $4.92K in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2026, filed 15 May 2026.